Synlogic’s proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including phenylketonuria (PKU) and enteric hyperoxaluria (HOX). The company is also building a portfolio of assets suitable for partnering in immunology and oncology . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Designer Genes: Synlogic Is Crafting Living Therapeutics Programmed to Treat Disease appeared first on GEN – Genetic Engineering and Biotechnology News.
